Peposertib Clinical Trials
6 recruitingDrug
Phase 16Phase 23
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1Phase 2
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Phase 1
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 1
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 1Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Pediatric Cancer
Gustave Roussy, Cancer Campus, Grand Paris472 enrolled21 locationsNCT02813135
Recruiting
Phase 1
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
GlioblastomaGliosarcoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT04555577